Although significant efficacy has been achieved with EGFR receptor tyrosine kinase inhibitors and immune checkpoint inhibitors in patients with EGFR mutation-positive and high PDL1-expressing LUAD, patients with LUAD still face a high risk of death due to the high propensity of lung cancer to postoperative recurrence and development of drug resistance [9]. This evidence concerns the gene EGFR and lung cancer.